Yoshiaki Fujimori

CIK: 0001233160

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (25.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

TAK

TAKEDA PHARMACEUTICAL CO LTD

Director

BZAI

Blaize Holdings, Inc.

Director

BSX

BOSTON SCIENTIFIC CORP

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

BZAI
Blaize Holdings, Inc.
Dec 3, 2025
Award(A)
Direct
75.3K shares-
BSX
BOSTON SCIENTIFIC CORP
Jul 29, 2025
Sale(S)
Direct
2.9K shares at avg. $106.99$310K
BZAI
Blaize Holdings, Inc.
Jun 28, 2025
Award(A)
Direct
94.4K shares-
BSX
BOSTON SCIENTIFIC CORP
May 8, 2025
Award(A)
Direct
2.1K shares-

		Type	Shares	Price		Ownership
Dec 3, 2025	BZAI Blaize Holdings, Inc.	Award(A)	75,258	-	-	Direct
Jul 29, 2025	BSX BOSTON SCIENTIFIC CORP	Sale(S)	2,901	$106.99	$310,378	Direct
Jun 28, 2025	BZAI Blaize Holdings, Inc.	Award(A)	94,361	-	-	Direct
May 8, 2025	BSX BOSTON SCIENTIFIC CORP	Award(A)	2,081	-	-	Direct

1-4 of 4 transactions

About FUJIMORI YOSHIAKI

FUJIMORI YOSHIAKI (SEC CIK 0001233160) files insider reports with the SEC as Director of TAKEDA PHARMACEUTICAL CO LTD (TAK), Director of Blaize Holdings, Inc. (BZAI) and Director of BOSTON SCIENTIFIC CORP (BSX).

Signal8 holds 6 ownership filings by FUJIMORI YOSHIAKI (2 Form 3, 4 Form 4), filed between Jan 15, 2025 and Mar 18, 2026. Those filings report 4 transactions, from May 8, 2025 to Dec 3, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on FUJIMORI YOSHIAKI's filings is in MARLBOROUGH, MA.

Recent filings by FUJIMORI YOSHIAKI

Dec 3, 2025: Grant or award of BZAI shares (Form 4, code A).
Jul 29, 2025: Open-market sale of BSX shares (Form 4, code S).
Jun 28, 2025: Grant or award of BZAI shares (Form 4, code A).
May 8, 2025: Grant or award of BSX shares (Form 4, code A).

Other insiders filing for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Duprey Lauren Rusckowski, Chief Transformation Officer
Plump Andrew Stewart, President, R&D
Greenway Nicola Deidre Petal, Chief Human Resources Officer
Farajallah Awny Samaan Botros, Chief Medical Officer
Ibrahim Ramy Riad Ahmed, President, PDT BU
Pacheco Rhonda Janice, President, U.S. Business Unit

How to read Form 4 transaction codes